WiseGuyReports.Com Publish a New Market Research Report On –“ Colorectal Cancer Drugs Market 2018 Global Share,Trend,Segmentation and Forecast to 2023”.

New York, NY -- (SBWire) -- 03/14/2018 --Colorectal cancer is also known as bowel cancer. It refers to the abnormal growth of the cells in colon and rectum due to cancer. Colorectal cancer starts either in the colon and rectum. Cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain.

Global colorectal cancer market is driven by some of the major factors such as increasing prevalence of colorectal cancer, technological advancements in the cancer therapy, aging population, and raise in consumer awareness about colorectal cancers. However, high costs of screening tests and drugs, lack of knowledge are some of the restraints that are hampering the growth of the global colorectal cancer drugs market.

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/2753870-global-colorectal-cancer-drugs-market-market-estimation-dynamics-regional-share

For more information or any query mail at sales@wiseguyreports.com

The global colorectal cancer drugs market is segmented by therapy, drug class, distribution channel, and regions.

On the basis of therapy, global colorectal cancer drugs market is segmented as
Adjuvant chemotherapy
Palliative chemotherapy
Immuno therapy
Neo adjuvant chemotherapy

On the basis of drug class, global colorectal cancer drugs market is segmented as
Capecitabine (Xeloda)
Irinotecan (Camptosar)
Fluorouracil (5-FU, Adrucil)
Trifluridine/tipiracil (TAS-102, Lonsurf)
Oxaliplatin (Eloxatin)
Others

Some common treatment regimens using these drugs include:
5-FU
Capecitabine, an oral form of 5-FU

5-FU with leucovorin (Wellcovorin), a vitamin that improves the effectiveness of 5-FU
FOLFIRI: 5-FU with leucovorin and irinotecan
FOLFOX: 5-FU with leucovorin and oxaliplatin
Irinotecan alone
XELOX/CAPEOX: Capecitabine with oxaliplatin
XELIRI/CAPIRI: Capecitabine with irinotecan

On the basis of distribution channel, the global colorectal cancer drugs market is segmented as
Retail Pharmacies
Hospital Pharmacies
Others

Colorectal cancer is the third most common cancer in the world. Huge government initiatives taken by the nations are booming up the growth of the colorectal cancer drugs treatment market globally. Biologics such as Zaltrap (Ziv-Aflibercept), Erbitux (Cetuximab), Avastin (Bevacizumab) are using rapidly for the treatment for colorectal cancer that are used as a targeted therapy and they acts only on the malignant cells. Market players in the colorectal cancer drugs market forming strategic alliances and partnerships to increase their market share.

Geographically, global colorectal cancer treatment market is segmented into five key regions such as Latin America, North America, Asia-Pacific, Europe and The Middle East and Africa. North America expected to grow at significant rate in colorectal cancer drugs market owing to the growing incidence of colorectal cancer and widespread awareness about early diagnosis and treatment of colorectal cancer. Asia Pacific region expected to have rapid growth in the market during the forecast period owing to huge population densities and high incidence of colorectal cancer in countries such as India and China.

Some of the players in the colorectal cancer drugs market are Amgen Inc. (U.S), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), and Sanofi (France) to name a few.

Report Details @ https://www.wiseguyreports.com/reports/2753870-global-colorectal-cancer-drugs-market-market-estimation-dynamics-regional-share

Table Of Contents – Major Key Points

1. Executive summary

2. Global Colorectal Cancer Drugs Market Introduction
2.1. Global Colorectal Cancer Drugs Market– Taxonomy
2.2. Global Colorectal Cancer Drugs Market–Definitions
2.2.1. Drug Type
2.2.2. Therapy

3. Global Colorectal Cancer Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Colorectal Cancer Drugs Market Dynamics – Factors Impact Analysis
3.6. Global Colorectal Cancer Drugs Market– Recent Market Introductions

4. Global Colorectal Cancer Drugs Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. Global Colorectal Cancer Drugs Market Forecast, By Therapy, 2012 - 2016 and Forecast, 2017 - 2023
5.1. Adjuvant Chemotherapy
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Palliative Chemotherapy
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Immuno Therapy
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Neo Adjuvant Chemotherapy
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis

6. Global Colorectal Cancer Drugs Market Forecast, By Drug Type, 2012 - 2016 and Forecast, 2017 - 2023
6.1. Capecitabine
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Irinotecan
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Fluorouracil
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Trifluridine/tipiracil
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Oxaliplatin
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
6.6. Others
6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.6.3. Market Opportunity Analysis

Continue……

For more information or any query mail at sales@wiseguyreports.com

About Wise Guy Reports
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.